IN8bio reports promising phase 1 results for leukemia therapy
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
GlobalData on MSN10h
TC BioPharm completes dosing in Cohort A of Phase IIb trial for AML
The trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.
The Lancet20h
Identifying key randomised clinical trials that could transform clinical care and public health
Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...
The Lancet20h
Largest trial of AI in breast cancer screening launched
The UK's National Health Service (NHS) has launched the world's largest prospective trial of using artificial intelligence (AI) to assess routine mammogram screenings. Nearly 700 000 women who have ...